| 1. |
The UK Department of Health has announced that it will provide health professionals with revised guidelines regarding contraception, sexual and reproductive health |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1449,
2004,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 2. |
MCC vaccination schedule needs a boost |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1449,
2004,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 3. |
Oseltamivir warranted for influenza among paediatric individuals? |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1449,
2004,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 4. |
Infliximab, etanercept worthwhile for RA in Spain? |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1449,
2004,
Page 5-6
&NA;,
Preview
|
|
摘要:
Rheumatoid arthritis (RA) is a chronic autoimmune disease that causes pain, swelling and stiffness in peripheral joints. RA is one of the most debilitating forms of arthritis, with joint destruction and bone erosion a hallmark of the disease. Indeed, in advanced stages, RA can be crippling, and require lifelong treatment and often surgery. While there is no cure for the disease, drug treatment can help to reduce pain and inflammation, and slow the progression of joint damage. Due to its chronic nature and the potential for disability, RA is associated with high healthcare resource use and costs. In Spain, the annual cost attributable to RA has been estimated at euro1 billion−euro2 billion. Consequently, therapies that can treat patients with RA in a cost-effective manner are important. Two studies which examined the cost effectiveness of RA treatments in Spain were presented at a poster session at the Annual European Congress of Rheumatology(EULAR) [Berlin, Germany, June 2004].
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 5. |
Use of a single LMWH affordable for UK hospitals |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1449,
2004,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 6. |
XMP 629*gel may reduce erythema, itching and lesion count in patients with moderate to very severe acne, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1449,
2004,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 7. |
Panitumumab lacks efficacy in metastatic renal cancer? |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1449,
2004,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 8. |
Darifenacin improves symptoms in overactive bladder |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1449,
2004,
Page 9-10
RM Poole,
Preview
|
|
摘要:
Darifenacin [Enablex, Emselex], a muscarinic M3-selective receptor antagonist, improves symptoms in patients with overactive bladder, according to studies presented at the 99th Annual Meeting of the American Urological Association (AUA) [San Francisco, US; May 2004]. A pooled analysis of data from three phase III studies involving a total of > 1000 patients showed that once-daily treatment with darifenacin 7.5mg or 15mg produced significant reductions in incontinence episodes, micturition frequency and urinary urgency. Another study presented at the meeting showed that the incidence of nocturia, a core symptom of overactive bladder, was significantly reduced in darifenacin, compared with placebo, recipients.
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 9. |
Transcriptional profiling: prediction of response to chemotherapy |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1449,
2004,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 10. |
Efalizumab [Raptiva] is an effective long-term treatment in adults with moderate-to-severe chronic plaque psoriasis, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1449,
2004,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
首页
